Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Spain: Researchers have found in a real-world cohort of patients with giant cell arteritis–associated aortitis, published in ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...

Highlights from CTAD 2025 include GLP-1 agonist data, p-tau217 biomarker utility, subcutaneous lecanemab trials, and racial disparities in trial enrollment.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...